sorafenib has been researched along with pargyline in 2 studies
Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (pargyline) | Trials (pargyline) | Recent Studies (post-2010) (pargyline) |
---|---|---|---|---|---|
6,520 | 730 | 5,251 | 2,811 | 27 | 295 |
Protein | Taxonomy | sorafenib (IC50) | pargyline (IC50) |
---|---|---|---|
Amine oxidase [flavin-containing] B | Rattus norvegicus (Norway rat) | 1.535 | |
Amine oxidase [flavin-containing] A | Homo sapiens (human) | 2.8888 | |
Amine oxidase [flavin-containing] B | Homo sapiens (human) | 0.5031 | |
Renin | Callithrix jacchus (white-tufted-ear marmoset) | 2.6 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
Chen, C; Chu, X; Geng, J; Han, D; Huang, M; Lei, Z; Wang, C; Wang, L; Wang, T; Wang, Y; Xie, T | 1 |
2 other study(ies) available for sorafenib and pargyline
Article | Year |
---|---|
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cyclopropanes; Drug Resistance, Neoplasm; Histone Demethylases; Humans; Liver Neoplasms; Male; Mice, Nude; Molecular Targeted Therapy; Neoplastic Stem Cells; Niacinamide; Pargyline; Phenotype; Phenylurea Compounds; Protein Kinase Inhibitors; RNA Interference; Sorafenib; Time Factors; Transfection; Tumor Burden; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2017 |